应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06978 永泰生物-B
休市中 04-11 16:08:19
3.950
+0.300
+8.22%
最高
4.270
最低
3.640
成交量
15.50万
今开
3.640
昨收
3.650
日振幅
17.26%
总市值
20.33亿
流通市值
20.33亿
总股本
5.15亿
成交额
58.46万
换手率
0.03%
流通股本
5.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
复旦张江：公司将适时推进与DeepSeek的接入工作以助力创新药物研究开发
证券之星 · 03-11
复旦张江：公司将适时推进与DeepSeek的接入工作以助力创新药物研究开发
卡达沙“头对头”击败泰瑞沙：中国肿瘤药市场能否迎分水岭时刻？
21世纪经济报道 · 03-11
卡达沙“头对头”击败泰瑞沙：中国肿瘤药市场能否迎分水岭时刻？
复星自研肺癌创新药上市申请获国家药监局受理
中金在线 · 03-11
复星自研肺癌创新药上市申请获国家药监局受理
港股异动 | 中国生物制药(01177)涨超4% 自研创新药“罗伐昔替尼”IB/IIA期临床研究结果发表于《血液》
智通财经 · 03-11
港股异动 | 中国生物制药(01177)涨超4% 自研创新药“罗伐昔替尼”IB/IIA期临床研究结果发表于《血液》
港股创新药概念股走强，相关ETF涨约2%
每日经济新闻 · 03-11
港股创新药概念股走强，相关ETF涨约2%
永泰生物-B盘中异动 早盘快速跳水6.30%报4.310港元
市场透视 · 03-11
永泰生物-B盘中异动 早盘快速跳水6.30%报4.310港元
创新药企融资闸口开启在望？百利天恒再向市场融资39亿
华尔街见闻 · 03-10
创新药企融资闸口开启在望？百利天恒再向市场融资39亿
广生堂(300436.SZ)：乙肝治疗创新药GST-HG131联合GST-HG141的II期临床研究获得优化审评审批试点项目确认书
格隆汇 · 03-10
广生堂(300436.SZ)：乙肝治疗创新药GST-HG131联合GST-HG141的II期临床研究获得优化审评审批试点项目确认书
H股IPO刚二次递表，800亿市值创新药“新贵”百利天恒又抛39亿A股定增案
钛媒体 · 03-10
H股IPO刚二次递表，800亿市值创新药“新贵”百利天恒又抛39亿A股定增案
A股药企再融资众生相
北京商报 · 03-10
A股药企再融资众生相
【广生堂：乙肝治疗创新药II期临床研究获得优化审评审批试点项目确认书】广生堂(300436.SZ)公告称，公司创新药控股子公司福建广生中霖生物科技有限公司收到北京市药品监督管理局下发的《优化创新药临床试验审评审批试点项目确认书》，同意GST-HG131联合GST-HG141的II期临床研究纳入试点项目，将有效缩短临床审评审批周期。GST-HG131是乙肝口服表面抗原抑制剂，目前全球范围内尚无同类产品上市；GST-HG141是新型乙肝核心蛋白或核衣壳调节剂，属于全新机制的在研抗乙肝病毒的一类新药。两者联合方案旨在探索基于核苷（酸）类似物NUC基础治疗上，在慢性乙型肝炎患者中的安全性、耐受性、有效性。该联合方案涉及的单药项目均已立项研发八年。
金融界 · 03-10
【广生堂：乙肝治疗创新药II期临床研究获得优化审评审批试点项目确认书】广生堂(300436.SZ)公告称，公司创新药控股子公司福建广生中霖生物科技有限公司收到北京市药品监督管理局下发的《优化创新药临床试验审评审批试点项目确认书》，同意GST-HG131联合GST-HG141的II期临床研究纳入试点项目，将有效缩短临床审评审批周期。GST-HG131是乙肝口服表面抗原抑制剂，目前全球范围内尚无同类产品上市；GST-HG141是新型乙肝核心蛋白或核衣壳调节剂，属于全新机制的在研抗乙肝病毒的一类新药。两者联合方案旨在探索基于核苷（酸）类似物NUC基础治疗上，在慢性乙型肝炎患者中的安全性、耐受性、有效性。该联合方案涉及的单药项目均已立项研发八年。
翰森制药创新药阿美乐?获药品注册证书
财中社 · 03-10
翰森制药创新药阿美乐?获药品注册证书
AI成创新药研发“加速器” 创新产业链加速整合
新华财经 · 03-10
AI成创新药研发“加速器” 创新产业链加速整合
健康元：公司股价受多种因素影响，正推动创新药管线开发
证券之星 · 03-10
健康元：公司股价受多种因素影响，正推动创新药管线开发
百利天恒拟募资不超过39亿元，用于创新药研发
环球网 · 03-10
百利天恒拟募资不超过39亿元，用于创新药研发
永泰生物-B盘中异动 急速上涨5.20%报4.650港元
市场透视 · 03-10
永泰生物-B盘中异动 急速上涨5.20%报4.650港元
众生药业：创新药研发是医药企业实现长期发展的必由之路
证券之星 · 03-10
众生药业：创新药研发是医药企业实现长期发展的必由之路
港股创新药ETF规模、份额连续两日创新高，三生制药涨超5%，机构：创新药板块情绪回暖
21世纪经济报道 · 03-10
港股创新药ETF规模、份额连续两日创新高，三生制药涨超5%，机构：创新药板块情绪回暖
云顶新耀(01952)“AI+创新药”第一股成港股18A黑马
智通财经 · 03-10
云顶新耀(01952)“AI+创新药”第一股成港股18A黑马
加载更多
公司概况
公司名称：
永泰生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。
发行价格：
--
{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":3.95,"timestamp":1744358899022,"preClose":3.65,"halted":0,"volume":155000,"delay":0,"floatShares":514584000,"shares":514584000,"eps":-0.38693168977847414,"marketStatus":"休市中","change":0.3,"latestTime":"04-11 16:08:19","open":3.64,"high":4.27,"low":3.64,"amount":584550,"amplitude":0.172603,"askPrice":0,"askSize":0,"bidPrice":4.12,"bidSize":3000,"shortable":0,"etf":0,"ttmEps":-0.38693168977847414,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1744594200000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":3.65,"openAndCloseTimeList":[[1744335000000,1744344000000],[1744347600000,1744358400000]],"volumeRatio":0.34753363216231975,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2518797077","title":"复旦张江：公司将适时推进与DeepSeek的接入工作以助力创新药物研究开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2518797077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518797077?lang=zh_cn&edition=full","pubTime":"2025-03-11 17:12","pubTimestamp":1741684327,"startTime":"0","endTime":"0","summary":"证券之星消息，复旦张江03月11日在投资者关系平台上答复投资者关心的问题。请问贵公司是否已经部署了DeepSeek？公司接入DeepSeek有哪些成本、收益方面的考量？如果公司计划在未来再进行部署，计划将DeepSeek应用于什么具体的业务呢？DeepSeek为开源大模型，个人及企业均可通过公开渠道获取使用。公司将适时推进与DeepSeek的接入工作，以助力创新药物的研究开发及/或其他工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100030040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","01349","688505"],"gpt_icon":0},{"id":"2518762891","title":"卡达沙“头对头”击败泰瑞沙：中国肿瘤药市场能否迎分水岭时刻？","url":"https://stock-news.laohu8.com/highlight/detail?id=2518762891","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518762891?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:13","pubTimestamp":1741677196,"startTime":"0","endTime":"0","summary":"继百济神州泽布替尼“头对头”完胜伊布替尼之后，又一家创新药企宣布，“头对头”击败肺癌药物明星品种奥希替尼。近日，同源康医药发布重磅公告，其自主研发的第三代EGFR抑制剂TY-9591（商品名：卡达沙?）在对比奥希替尼（商品名：泰瑞沙?）作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验中，达到了研究预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503113342350648.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503113342350648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2518676495","title":"复星自研肺癌创新药上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2518676495","media":"中金在线","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518676495?lang=zh_cn&edition=full","pubTime":"2025-03-11 14:47","pubTimestamp":1741675630,"startTime":"0","endTime":"0","summary":"近日，复星国际旗下子公司复星医药宣布，其自主研发的1类新药丁二酸复瑞替尼胶囊的上市申请已获国家药品监督管理局受理。该新药主要用于治疗ALK阳性非小细胞肺癌、ROS1阳性非小细胞肺癌等，本次申报适应症为用于间变性淋巴瘤激酶阳性的局部晚期或转移性非小细胞肺癌患者的治疗。在2024年世界肺癌大会期间，复瑞替尼治疗ALK阳性非小细胞肺癌的III期REMARK研究的期中分析结果以最新突破性摘要形式公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031114505896410ad2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031114505896410ad2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","06978","BK1515","600196","BK1161","00656","BK1191","BK1574","BK1593"],"gpt_icon":0},{"id":"2518535267","title":"港股异动 | 中国生物制药(01177)涨超4% 自研创新药“罗伐昔替尼”IB/IIA期临床研究结果发表于《血液》","url":"https://stock-news.laohu8.com/highlight/detail?id=2518535267","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518535267?lang=zh_cn&edition=full","pubTime":"2025-03-11 11:11","pubTimestamp":1741662694,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药涨超4%，截至发稿，涨4.48%，报3.5港元，成交额2.03亿港元。消息面上，3月10日，中国生物制药发布公告，该集团自主研发的国家1类创新药“罗伐昔替尼”用于治疗慢性移植物抗宿主病的Ib/IIa 期临床研究结果已发表于国际血液学领域顶级期刊《血液》。据悉，JAK和ROCK是调控免疫反应和纤维化进程的两大关键信号通路。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","01177","BK1515","06978","BK1191","BK1161","BK1574","BK1589","BK1521"],"gpt_icon":0},{"id":"2518585817","title":"港股创新药概念股走强，相关ETF涨约2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518585817","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518585817?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:46","pubTimestamp":1741661160,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 每经记者 叶峰 每经编辑 肖芮冬 港股创新药概念股走强，中国生物制药涨超4%，百济神州涨超3%，信达生物、康方生物、翰森制药涨超2%。受盘面影响，多只港股创新药相关ETF涨约2%。有券商表示，随着AI医疗的崛起和产业快速跟进，2025年医药投资迎来重大变局，建议重点把握创新成长赛道，“AI+医药”和创新药两大增长板块将是2025年医药投资的最重要战场。此外，医药板块在2025一季报后的业绩复苏和困境反转也值得一定关注。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-03-11/doc-inepfzst2797279.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-03-11/doc-inepfzst2797279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HSTECH","FDN","06978","159992","BK4550","BK4585","BK1161","HSCEI","BK1574","YANG","BK4614","BK4588"],"gpt_icon":0},{"id":"2518677730","title":"永泰生物-B盘中异动 早盘快速跳水6.30%报4.310港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518677730","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518677730?lang=zh_cn&edition=full","pubTime":"2025-03-11 09:33","pubTimestamp":1741656808,"startTime":"0","endTime":"0","summary":"2025年03月11日早盘09时33分，永泰生物-B股票出现波动，股价快速下挫6.30%。截至发稿，该股报4.310港元/股，成交量1.1万股，换手率0.00%，振幅3.26%。资金方面，该股资金流入3.512万港元，流出1.308万港元。永泰生物-B股票所在的生物技术行业中，整体跌幅为0.07%。其相关个股中，荃信生物-B、百济神州、东曜药业-B涨幅较大，振幅较大的相关个股有方达控股、科伦博泰生物-B、欧康维视生物-B，振幅分别为10.58%、6.59%、6.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311093328abf4847a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311093328abf4847a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2518206311","title":"创新药企融资闸口开启在望？百利天恒再向市场融资39亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2518206311","media":"华尔街见闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518206311?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:59","pubTimestamp":1741629598,"startTime":"0","endTime":"0","summary":"左手A股，右手港股？","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/75676f6b-e7dd-480a-a579-4445276b4042.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/75676f6b-e7dd-480a-a579-4445276b4042.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3742754","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3742754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2518221805","title":"广生堂(300436.SZ)：乙肝治疗创新药GST-HG131联合GST-HG141的II期临床研究获得优化审评审批试点项目确认书","url":"https://stock-news.laohu8.com/highlight/detail?id=2518221805","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518221805?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:05","pubTimestamp":1741611951,"startTime":"0","endTime":"0","summary":"2025年3月10日，福建广生堂药业股份有限公司创新药控股子公司福建广生中霖生物科技有限公司收到北京市药品监督管理局下发的《优化创新药临床试验审评审批试点项目确认书》，同意GST-HG131联合GST-HG141的II期临床研究纳入试点项目，将有效缩短临床审评审批周期。2025年1月，GST-HG131已按照II期临床方案要求完成了计划例数全部的患者入组。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/10210548635518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300436","06978","GST","BK1574","BK0239","BK1161","159992"],"gpt_icon":0},{"id":"2518226917","title":"H股IPO刚二次递表，800亿市值创新药“新贵”百利天恒又抛39亿A股定增案","url":"https://stock-news.laohu8.com/highlight/detail?id=2518226917","media":"钛媒体","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518226917?lang=zh_cn&edition=full","pubTime":"2025-03-10 20:45","pubTimestamp":1741610716,"startTime":"0","endTime":"0","summary":"A股上市两年，800亿市值创新药“新贵”百利天恒-U抛出再融资计划。3月10日，百利天恒公告称，公司拟向特定对象发行A股股票并募集资金不超过39亿元（含本数），扣除发行费用后，将全部用于创新药研发项目。但截至2024年9月末，该募资已累计使用7.66亿元，所剩无几。2024年5月，百利天恒即启动港股IPO，并于7月首次递表。今年1月21日，百利天恒二次递表。2024年，公司收到8亿美元不可撤销的首付款。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/10204548634912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06978","159982","399300","688506","BK1574","159992","BK0239","BK1161"],"gpt_icon":0},{"id":"2518911226","title":"A股药企再融资众生相","url":"https://stock-news.laohu8.com/highlight/detail?id=2518911226","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518911226?lang=zh_cn&edition=full","pubTime":"2025-03-10 20:43","pubTimestamp":1741610606,"startTime":"0","endTime":"0","summary":"3月10日，百利天恒（688506）抛出了一则不超39亿元的定增募资计划，年内A股药企再融资再添一例。就在同一天，同为创新药企的迪哲医药披露了定增注册稿，距离发行又近一步。而在上个月月底，海思科也披露公告称，公司拟定增募资不超13.65亿元。北京商报记者注意到，上述拟定增募资的医药股，募集资金大部分都计划投向创新药项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503103341479054.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503103341479054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2518622835","title":"【广生堂：乙肝治疗创新药II期临床研究获得优化审评审批试点项目确认书】广生堂(300436.SZ)公告称，公司创新药控股子公司福建广生中霖生物科技有限公司收到北京市药品监督管理局下发的《优化创新药临床试验审评审批试点项目确认书》，同意GST-HG131联合GST-HG141的II期临床研究纳入试点项目，将有效缩短临床审评审批周期。GST-HG131是乙肝口服表面抗原抑制剂，目前全球范围内尚无同类产品上市；GST-HG141是新型乙肝核心蛋白或核衣壳调节剂，属于全新机制的在研抗乙肝病毒的一类新药。两者联合方案旨在探索基于核苷（酸）类似物NUC基础治疗上，在慢性乙型肝炎患者中的安全性、耐受性、有效性。该联合方案涉及的单药项目均已立项研发八年。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518622835","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518622835?lang=zh_cn&edition=full","pubTime":"2025-03-10 19:58","pubTimestamp":1741607924,"startTime":"0","endTime":"0","summary":"广生堂(300436.SZ)公告称，公司创新药控股子公司福建广生中霖生物科技有限公司收到北京市药品监督管理局下发的《优化创新药临床试验审评审批试点项目确认书》，同意GST-HG131联合GST-HG141的II期临床研究纳入试点项目，将有效缩短临床审评审批周期。GST-HG131是乙肝口服表面抗原抑制剂，目前全球范围内尚无同类产品上市；GST-HG141是新型乙肝核心蛋白或核衣壳调节剂，属于全新机制的在研抗乙肝病毒的一类新药。两者联合方案旨在探索基于核苷（酸）类似物NUC基础治疗上，在慢性乙型肝炎患者中的安全性、耐受性、有效性。该联合方案涉及的单药项目均已立项研发八年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/10195848633983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159837","BK1576","GST","BK1583","BK1574","03347","159992","300436","06978","BK0239","BK1141","BK1161"],"gpt_icon":0},{"id":"2518211009","title":"翰森制药创新药阿美乐?获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2518211009","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518211009?lang=zh_cn&edition=full","pubTime":"2025-03-10 17:08","pubTimestamp":1741597724,"startTime":"0","endTime":"0","summary":"3月10日，翰森制药（03692）发布公告，宣布其创新药阿美乐?（甲磺酸阿美替尼片）获得中国国家药品监督管理局（NMPA）签发的药品注册证书，批准增加新的适应症。这一新适应症是针对经过铂类根治性放化疗后未出现疾病进展的不可切除的局部晚期非小细胞肺癌（NSCLC）患者。这是阿美乐?获批的第三项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503103341315312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1574","06978","BK1191","BK1589","BK1161","03692"],"gpt_icon":0},{"id":"2518388218","title":"AI成创新药研发“加速器” 创新产业链加速整合","url":"https://stock-news.laohu8.com/highlight/detail?id=2518388218","media":"新华财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518388218?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:16","pubTimestamp":1741594591,"startTime":"0","endTime":"0","summary":"新华财经上海3月10日电随着AI迅猛发展，其对医药行业的重塑也逐渐引发关注。尤其是在创新药领域，AI技术已全方位渗透到各环节，从基础研究到临床试验，从靶点发现到药物分子设计，都带来新突破。近日，云顶新耀宣布，其自主研发的新型mRNA个性化疫苗EVM16完成首例患者给药，成功进入临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503103341261663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2518908682","title":"健康元：公司股价受多种因素影响，正推动创新药管线开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2518908682","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518908682?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:06","pubTimestamp":1741593989,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价已经10年期间都没有涨了。要对股东投资者有一个正确的反馈.健康元回复：你好，公司股价受行业、整体市场、公司基本面及业绩表现等多种因素影响。我们会尽全力推动创新药管线的开发，力争以优良的业绩回报广大投资者，同时加强跟资本市场对我们创新药努力的沟通。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000019675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380","BK0077","BK0046","BK0188","06978","BK0028","BK0239","BK1574","BK1161","BK0114","159992"],"gpt_icon":0},{"id":"2518048291","title":"百利天恒拟募资不超过39亿元，用于创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2518048291","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518048291?lang=zh_cn&edition=full","pubTime":"2025-03-10 15:58","pubTimestamp":1741593526,"startTime":"0","endTime":"0","summary":"3月10日，百利天恒发布了2025年度向特定对象发行A股股票预案，计划向特定对象发行A股股票并募集资金不超过39亿元，扣除发行费用后，全部资金将用于创新药研发项目。百利天恒表示，通过本次募投项目的实施，将加快创新药物的研发进程，拓展在研产品布局的深度和广度，为更多产品的商业化奠定坚实基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.huanqiu.com/article/4Lny1ptiGfo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_huanqiu","symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2518529883","title":"永泰生物-B盘中异动 急速上涨5.20%报4.650港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518529883","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518529883?lang=zh_cn&edition=full","pubTime":"2025-03-10 13:04","pubTimestamp":1741583046,"startTime":"0","endTime":"0","summary":"2025年03月10日下午盘13时04分，永泰生物-B股票出现波动，股价急速上涨5.20%。截至发稿，该股报4.650港元/股，成交量23.2万股，换手率0.05%，振幅4.75%。资金方面，该股资金流入39.125万港元，流出54.419万港元。永泰生物-B股票所在的生物技术行业中，整体跌幅为2.57%。其相关个股中，同源康医药-B、和铂医药-B、奥星生命科技涨幅较大，振幅较大的相关个股有同源康医药-B、来凯医药-B、科笛-B，振幅分别为35.78%、20.08%、19.70%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310130406a269644c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310130406a269644c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2518268627","title":"众生药业：创新药研发是医药企业实现长期发展的必由之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2518268627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518268627?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:37","pubTimestamp":1741577837,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业03月10日在投资者关系平台上答复投资者关心的问题。创新药研发确实具有高投入、高风险的特点，但这也是医药企业实现长期发展的必由之路。公司按照“中药为基、创新引领，聚焦特色的医药健康企业”的战略目标定位，始终坚持以创新驱动发展，聚焦代谢性疾病、呼吸系统疾病等领域，积极推进创新药研发。未来伴随着更多产品的上市，也将为公司的盈利能力提供助力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000010448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK0077","BK1574","159992","06978","BK1161"],"gpt_icon":0},{"id":"2518251237","title":"港股创新药ETF规模、份额连续两日创新高，三生制药涨超5%，机构：创新药板块情绪回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2518251237","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518251237?lang=zh_cn&edition=full","pubTime":"2025-03-10 10:17","pubTimestamp":1741573035,"startTime":"0","endTime":"0","summary":"相关ETF方面，港股创新药ETF一度涨超1.1%，截至发稿飘红，涨0.27%，换手率近16%，成交额近8000万元，溢折率0.41%，盘中频现溢价交易。数据显示，港股创新药ETF最新流通规模、最新流通份额连续两日创历史新高。港股创新药ETF紧密跟踪港股通创新药指数，该指数反映港股通生物科技产业上市公司的运行特征。近期受益于海外流动性因素，创新药板块情绪回暖，前期的超跌有所修复，市场风险偏好逐步回升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310102505abf20fd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310102505abf20fd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","06978","01530","BK1593","BK1161"],"gpt_icon":0},{"id":"2518237693","title":"云顶新耀(01952)“AI+创新药”第一股成港股18A黑马","url":"https://stock-news.laohu8.com/highlight/detail?id=2518237693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518237693?lang=zh_cn&edition=full","pubTime":"2025-03-10 08:14","pubTimestamp":1741565690,"startTime":"0","endTime":"0","summary":"港股创新药企云顶新耀已实现异军突起，凭借多项专有技术率先实现从“18A创新药”公司到具备专有技术的“AI科技+创新制药”公司的跨越。当日该公司股价顺势涨至超过60港元，创下近三年半新高，并成功突破2020年IPO发行价，被业内称为“AI+创新药”第一股。而云顶新耀凭借AI驱动的自主知识产权的 mRNA 技术平台，多路径布局肿瘤及其他治疗性 mRNA 药物研发，且拥有相关产品的全部知识产权及全球权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4614","BK1583","BK1574","159992","HSCEI","06978","HSTECH","YANG","BK1161","01952"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.034},{"period":"1month","weight":-0.0835},{"period":"3month","weight":0.6597},{"period":"6month","weight":0.7634},{"period":"1year","weight":0.1862},{"period":"ytd","weight":0.7174}],"compareEarnings":[{"period":"1week","weight":-0.0847},{"period":"1month","weight":-0.1138},{"period":"3month","weight":0.0971},{"period":"6month","weight":-0.0159},{"period":"1year","weight":0.2234},{"period":"ytd","weight":0.0426}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.065686},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.084188},{"month":5,"riseRate":0.5,"avgChangeRate":0.017788},{"month":6,"riseRate":1,"avgChangeRate":0.116747},{"month":7,"riseRate":0,"avgChangeRate":-0.121182},{"month":8,"riseRate":0.4,"avgChangeRate":-0.037653},{"month":9,"riseRate":0.2,"avgChangeRate":-0.026649},{"month":10,"riseRate":0.6,"avgChangeRate":0.001262},{"month":11,"riseRate":0.6,"avgChangeRate":0.007893},{"month":12,"riseRate":0.8,"avgChangeRate":0.087803}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.4","shortVersion":"4.32.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}